Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Gutzmer R;Rivoltini L;Levchenko E;Testori A;Utikal J;Ascierto PA;Demidov L;Grob JJ;Ridolfi R;Schadendorf D;Queirolo P;Santoro A;Loquai C;Dreno B;Hauschild A;Schultz E;Lesimple TP;Vanhoutte N;Salaun B;Gillet M;Jarnjak S;De Sousa Alves PM;Louahed J;Brichard VG;Lehmann FF

2016-01-01